Evidence map›Paper›PMID 35756618›Full record

ArticleFrontiers in oncology2022

Multi-Sequence MR-Based Radiomics Signature for Predicting Early Recurrence in Solitary Hepatocellular Carcinoma ≤5 cm.

Leyao Wang, Xiaohong Ma, Bing Feng, Shuang Wang, Meng Liang, Dengfeng Li, Sicong Wang, Xinming Zhao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Leyao WangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaohong MaDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bing FengDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuang WangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Meng LiangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dengfeng LiDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sicong WangMagnetic Resonance Imaging Research, General Electric Healthcare, Beijing, China.
Xinming ZhaoDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUnited Imaging Healthcare (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the value of radiomics features derived from preoperative multi-sequence MR images for predicting early recurrence (ER) in patients with solitary hepatocellular carcinoma (HCC) ≤5 cm. Methods: One hundred and ninety HCC patients were enrolled and allocated to training and validation sets (n = 133:57). The clinical-radiological model was established by significant clinical risk characteristics and qualitative imaging features. The radiomics model was constructed using the least absolute shrinkage and selection operator (LASSO) logistic regression algorithm in the training set. The combined model was formed by integrating the clinical-radiological risk factors and selected radiomics features. The predictive performance was assessed by the area under the receiver operating characteristic curve (AUC). Results: Arterial peritumoral hyperenhancement, non-smooth tumor margin, satellite nodules, cirrhosis, serosal invasion, and albumin showed a significant correlation with ER. The AUC of the clinical-radiological model was 0.77 (95% CI: 0.69-0.85) and 0.76 (95% CI: 0.64-0.88) in the training and validation sets, respectively. The radiomics model constructed using 12 radiomics features selected by LASSO regression had an AUC of 0.85 (95% CI: 0.79-0.91) and 0.84 (95% CI: 0.73-0.95) in the training and validation sets, respectively. The combined model further improved the prediction performance compared with the clinical-radiological model, increasing AUC to 0.90 (95% CI: 0.85-0.95) in the training set and 0.88 (95% CI: 0.80-0.97) in the validation set (p < 0.001 and p = 0.012, respectively). The calibration curve fits well with the standard curve. Conclusions: The predictive model incorporated the clinical-radiological risk factors and radiomics features that could adequately predict the individualized ER risk in patients with solitary HCC ≤5 cm.

Indexed as

early recurrencehepatocellular carcinomamagnetic resonance imagingnomogramradiomics

Identifiers

PMID35756618
PMCPMC9213728
OpenAlexW4281623984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.